Dianthus Therapeutics (DNTH) Long-Term Investments (2024 - 2025)
Dianthus Therapeutics' (DNTH) quarterly Long-Term Investments came in at $110.1 million in Q4 2025, up 34.76% year-on-year from $81.7 million in Q4 2024, and down 27.96% quarter-over-quarter from $152.9 million in Q3 2025.
Dianthus Therapeutics (DNTH) Long-Term Investments (2024 - 2025) Analysis & Trends
Dianthus Therapeutics' Long-Term Investments history runs 2 years deep, the most recent figure standing at $110.1 million for Q4 2025.
- On a quarterly basis, Long-Term Investments rose 34.76% year-over-year to $110.1 million in Q4 2025; TTM through Dec 2025 was $110.1 million, a 34.76% increase from a year earlier, with the FY2025 full-year figure at $110.1 million, up 34.76% from the prior year.
- Long-Term Investments fell to $110.1 million in Q4 2025 per DNTH's latest filing, from $152.9 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $152.9 million in Q3 2025 and bottomed at $51.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Dianthus Therapeutics | 3.37 Bn | 2.97 Bn | - | 110.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110.14 Mn |
| Sep 30, 2025 | 152.87 Mn |
| Jun 30, 2025 | 51.71 Mn |
| Mar 31, 2025 | 68.31 Mn |
| Dec 31, 2024 | 81.73 Mn |
| Sep 30, 2024 | 61.48 Mn |